Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group
| Autor: | Martin Kloeckner, Guillaume Baudry, Julien Jeanneteau, Alain Cohen-Solal, Théo Pezel, Thibaud Damy, Etienne Audureau, François Koukoui, Christian Godreuil, Marie Fertin, Ahmed Ben Driss, Thierry Laperche, Florence Durup, Jacques Mansourati, François Roubille, Lamia Kesri-Tartière |
|---|---|
| Přispěvatelé: | Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty lcsh:Diseases of the circulatory (Cardiovascular) system Iron [SDV]Life Sciences [q-bio] Heart failure 030204 cardiovascular system & hematology Guidelines 03 medical and health sciences 0302 clinical medicine Interquartile range Original Research Articles Internal medicine Diagnosis medicine Humans In patient Original Research Article Registries 030212 general & internal medicine Iron supplementation ComputingMilieux_MISCELLANEOUS Aged Ejection fraction Anemia Iron-Deficiency Adult patients business.industry Optimal treatment Iron deficiency Stroke Volume medicine.disease 3. Good health Clinical Practice lcsh:RC666-701 Cardiology and Cardiovascular Medicine business |
| Zdroj: | ESC Heart Failure ESC Heart Failure, Wiley, In press, ⟨10.1002/ehf2.13245⟩ ESC Heart Failure, Vol 8, Iss 2, Pp 1509-1521 (2021) |
| ISSN: | 2055-5822 |
| Popis: | Aims Iron deficiency (ID) occurs in about 50% of patients with heart failure (HF). The European Society of Cardiology (ESC) recommends ID diagnostic testing in newly diagnosed patients with HF and during follow‐up, with intravenous iron supplementation (IS) only recommended in patients with HF with reduced ejection fraction (HFrEF). This study aimed to assess prevalence, clinical characteristics, and application of ESC guidelines for ID and IS in patients with HF in the real‐life clinical setting. Methods and results The French transversal multicentre OFICSel registry (300 cardiologists) conducted in 2017 included patients hospitalized for HF at least once in the previous 5 years. Diverse adult patients were eligible including inpatients and outpatients and those with acute and chronic HF. Data were collected from cardiologists and patients using study‐specific surveys. Data included demographic and clinical data, as well as HF and ID management data. Overall, 2822 patients, mainly male (69.3%) with a median age of 69 years (interquartile range 58–78), were included. A total of 1075 patients (38.1%) were tested for ID, with 364 (33.9%) diagnosed. Of these, 168 (46.2%) received IS: 128 (76.2%) intravenous IS and 40 (23.8%) oral. Among the 201 patients with HFrEF diagnosed with ID, 99 (49.3%) received IS: 79 (79.8%) intravenous IS and 20 (20.2%) oral. Conclusions In clinical practice, only one‐third of patients with HF had a diagnostic test for ID. In patients with ID with HFrEF, only 39.3% received intravenous IS as recommended. Thus, in general, cardiologists should be encouraged to follow the ESC guidelines to ensure optimal treatment for patients with HF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text